Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03562468 · ClinicalTrials.gov registry record · NA
A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults
A NA study, sponsored by ChromaDex.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT03562468: Completed NA study, sponsored by ChromaDex.
NCT03562468 is a NA study that has completed, run by ChromaDex. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03562468, a NA study, has completed, sponsored by ChromaDex.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The sponsor of this study is ChromaDex, Inc. This is a double-blind, randomized, crossover study to investigate the effects of 300 mg/d and 1000 mg/d TRU NIAGEN (nicotinamide riboside) compared to a placebo control on cognitive function, mood and sleep in men and women over 55 years of age. The trial is managed by Midwest Center for Metabolic and Cardiovascular Research.
Primary Outcome
The primary outcome variable will be the difference between treatments in the change from baseline (defined as visit 2 value for each of the three treatment periods) in executive function measured with the CNS Vital Signs test battery, using the standard score.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT 300 mg/day of TRU NIAGEN (nicotinamide riboside)
- DIETARY_SUPPLEMENT 1000 mg/day of TRU NIAGEN (nicotinamide riboside)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-06-13 |
| Est. Completion | 2019-04-26 |
| Phase | NA |
What the finished NCT03562468 record still lists
NCT03562468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03562468 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03562468 about?
NCT03562468 is a clinical study titled "A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults". The sponsor of this study is ChromaDex, Inc. This is a double-blind, randomized, crossover study to investigate the effects of 300 mg/d and 1000 mg/d TRU NIAGEN (nicotinamide riboside) compared to a placebo control on cognitive function, mood and sleep in men and women over 55 years of age. The tria...
What is the current status of trial NCT03562468?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2018-06-13. Estimated completion is 2019-04-26.
What interventions are being tested in trial NCT03562468?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), 300 mg/day of TRU NIAGEN (nicotinamide riboside) (DIETARY_SUPPLEMENT), 1000 mg/day of TRU NIAGEN (nicotinamide riboside) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03562468?
This trial is sponsored by ChromaDex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03562468's enrollment target sits among peer trials
40 1447th of 2000 higher than 465 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI